



Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity

Kathryn A. Bowman,^a Daniel Stein,^b Sally Shin,^a Kathie G. Ferbas,^c Nicole H. Tobin,^c Colin Mann,^e Stephanie Fischinger,^a Erica Ollmann Saphire,^f Douglas Lauffenburger,^b Anne W. Rimoin,^e Grace Aldrovandi,^d  Galit Alter^a

^aRagon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA

^bDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

^cDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA

^dDepartment of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA

^eDepartment of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, USA

^fCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA

ABSTRACT Despite the robust immunogenicity of SARS-CoV-2 mRNA vaccines, emerging data have revealed enhanced neutralizing antibody and T cell cross-reactivity among individuals that previously experienced COVID-19, pointing to a hybrid immune advantage with infection-associated immune priming. Beyond neutralizing antibodies and T cell immunity, mounting data point to a potential role for additional antibody effector functions, including opsonophagocytic activity, in the resolution of symptomatic COVID-19. Whether hybrid immunity modifies the Fc-effector profile of the mRNA vaccine-induced immune response remains incompletely understood. Thus, here we profiled the SARS-CoV-2 specific humoral immune response in a group of individuals with and without prior COVID-19. As expected, hybrid Spike-specific antibody titers were enhanced following the primary dose of the mRNA vaccine but were similar to those achieved by naive vaccinees after the second mRNA vaccine dose. Conversely, Spike-specific vaccine-induced Fc-receptor binding antibody levels were higher after the primary immunization in individuals with prior COVID-19 and remained higher following the second dose compared to those in naive individuals, suggestive of a selective improvement in the quality, rather than the quantity, of the hybrid humoral immune response. Thus, while the magnitude of antibody titers alone may suggest that any two antigen exposures—either hybrid immunity or two doses of vaccine alone—represent a comparable prime/boost immunologic education, we find that hybrid immunity offers a qualitatively improved antibody response able to better leverage Fc-effector functions against conserved regions of the virus.

IMPORTANCE Recent data indicates improved immunity to SARS-CoV-2 in individuals who experience a combination of two mRNA vaccine doses and infection, “hybrid immunity,” compared to individuals who receive vaccination or experience infection alone. While previous infection accelerates the vaccine-induced immune response following the first dose of mRNA vaccination, subsequent doses demonstrate negligible increases in antibody titers or T cell immunity. Here, using systems serology, we observed a unique antibody profile induced by hybrid immunity, marked by the unique induction of robust Fc-recruiting antibodies directed at the conserved region of the viral Spike antigen, the S2-domain, induced at lower levels in individuals who only received mRNA vaccination. Thus, hybrid immunity clearly redirects vaccine-induced immunodominance, resulting in the induction of a robust functional humoral immune response to the most highly conserved region of the SARS-CoV-2 Spike antigen, which may be key to protection against existing and emerging variants of concern. Thus, next-generation vaccines able to mimic hybrid immunity and

Editor Thomas E. Morrison, University of Colorado School of Medicine

Copyright © 2022 Bowman et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Galit Alter, galter@partners.org, or Grace Aldrovandi, galdrovandi@mednet.ucla.edu.

The authors declare a conflict of interest. Galit Alter is a founder/equity holder in SeromYx Systems and Leyden Labs. G.A. has served as a scientific advisor for Sanofi Vaccines. G.A. has collaborative agreements with GSK, Merck, Sanofi, Pfizer, Medicago, BioNtech, Moderna, BMS, Novavax, SK Biosciences, Gilead, and Sanaria.

Received 8 June 2022

Accepted 18 July 2022

Published 24 August 2022

drive a balanced response to conserved regions of the Spike antigen may confer enhanced protection against disease.

KEYWORDS COVID-19, Fc-receptors, hybrid immunity, SARS-CoV-2, antibody function, vaccines

Despite the development of several highly protective COVID-19 vaccines, SARS-CoV-2 continues to spread across the globe due to incomplete global distribution of vaccines, waning immunity, and the evolution of variants of concern (1, 2). Currently, only 64.8% of the global population has received at least one dose of vaccine (3) and strategic boosting has been complicated by our incomplete understanding of the correlates of immunity against COVID-19 (4, 5). Although neutralizing antibodies clearly contribute to the blockade of viral transmission (6), persistent vaccine-induced protection against severe disease and death from several neutralization-resistant variants of concern supports a critical role for alternate vaccine-induced immunologic responses as key determinants of protection against disease. While T cells have been proposed in the control and clearance of infection after transmission, their direct association with disease severity remains unclear. Conversely, antibodies able to leverage the antiviral function of the immune response, via Fc receptors, have been associated with attenuated symptomatology (7) and survival of severe COVID-19 (8), were conserved for long periods of time (9), and maintained function across variants of concern (VOCs) (10). Non-neutralizing Fc-effector functions are important in protection against Influenza virus (11, 12), Ebola virus (13), as well as several bacterial infections (14, 15). These data support a critical role of these alternative antiviral functions of the humoral immune response to SARS-CoV-2.

Real-world vaccine efficacy revealed rapidly waning immunity following vaccination (16–18), prompting recommendations for booster vaccine doses 4 to 6 months following the primary vaccine series (19, 20). However, anecdotal studies have suggested fewer vaccine breakthroughs (21–24) and a slower decay in the antibody response (25) among individuals who had previously experienced COVID-19 prior to vaccination. Moreover, deeper immunological profiling indicated increased breadth and magnitude of the neutralizing antibody response in individuals with hybrid (infection + vaccination) compared to vaccine-only induced immunity (26–31). Similarly, individuals with hybrid immunity (infection + vaccination) produced a distinct population of functionally Th1-skewed IFN- γ and IL-10-expressing memory CD4⁺ (32) and CD8⁺ T cells (33) not observed in previously naive individuals. However, whether hybrid immunity also enhanced the Fc-effector profile of the vaccine-induced SARS-CoV-2 specific humoral response remained largely unknown.

As worldwide vaccination efforts continue, a much larger percentage will have previously recovered from natural infection prior to completing vaccination. Thus, understanding the impact of hybrid immunity on shaping the overall humoral immune response may provide key insights into correlates of immunity and guide boosting recommendations. Here, we comprehensively profiled the Fc landscape of mRNA-induced humoral immune responses across a cohort of individuals who had previously experienced COVID-19 or were infection-naive. Consistent with prior observations (26, 28, 34), we saw that SARS-CoV-2 vaccine specific titers increased in both the hybrid-immunity and infection-naive groups after the initial vaccine dose, albeit with higher titers in the hybrid-immunity group. As seen in prior studies (28, 31), previously infected individuals developed vaccine-induced responses after a single dose of either Pfizer BNT162b2 or Moderna mRNA-1273 mRNA vaccine which were similar in magnitude to antibody responses after two vaccine doses in infection-naive individuals. Conversely, we observed a significant increase in Fc-receptor (FcR) binding in previously infected individuals after the first dose which was further expanded after the second dose, potentially conferring broader functional protection against future infection. Thus, hybrid immunity may confer a gain in quality rather than quantity of the antibody response, which is not apparent on evaluation of titers or neutralizing capacity alone.

RESULTS

Vaccination-induced antibody response in previously infected and naive individuals. We comprehensively profiled the SARS-CoV-2 humoral immune response in a group of mRNA vaccinees, including 14 individuals previously infected with SARS-CoV-2 and 49 who were naive to SARS-CoV-2. The group included health care workers between the ages of 26 to 68, 35:32 women:men ratio, with 39 individuals who had received the Pfizer/BNT16b2 vaccine and 27 who had received the Moderna mRNA-1273 vaccine. Vaccine responses were profiled after the first dose of vaccination (prime, V1) and/or after the second dose (boost, V2) to compare the magnitude, quality, and kinetics of humoral responses after prime and boost in hybrid-immunity and infection-naive individuals. Antibody subclass, isotype, Fc-receptor binding levels, and antibody effector responses were profiled across the full D614G Spike, the S1-domain, the receptor binding domain (RBD), the S2 domain, and the N-terminal domain (NTD). Additionally, the antibody Fc region was simultaneously profiled by measuring isotype-specific responses (IgG1, IgG2, IgG3, IgG4, IgM, IgA1) and Fc γ R binding (Fc γ R2a, Fc γ R2b, Fc γ R3a, Fc γ R3b). Subsequently, Spike-specific antibody effector functions, including antibody dependent cellular phagocytosis (ADCP), antibody dependent neutrophil phagocytosis (ADNP), and antibody-dependent complement deposition (ADCD) were profiled (Fig. 1A).

Consistent with prior observations, after the first immunization, individuals with prior SARS-CoV-2 infection induced higher levels of S1-, RBD-, and S2-specific IgM, IgG1, and IgG2 compared to naive individuals (Fig. 1B). Conversely, there was minimal difference in the IgG3 and IgA responses across the groups, and this was limited to S2-specific responses. Interestingly, a single dose of mRNA did not induce appreciable NTD-specific antibody titers across the naive vaccinees, but did induce robust NTD-specific IgG1, IgG2, IgG3, and IgA titers in individuals who had been previously infected (Fig. 1B). After the second dose of mRNA, S1-specific IgG1, IgG2, IgG3, IgM, and IgA antibody titers rose significantly in vaccinated individuals, reaching levels equal or superior to those found in previously infected individuals. Unexpectedly, NTD- and S2-specific responses exhibited declining trends among previously infected individuals after the second dose. Thus, overall, the broader epitope-specific recognition observed in previously infected individuals diminished with a boost, with similar isotype titers across the two groups after boosting.

Beyond binding, antibody interactions with Fc-receptors drive antibody effector functions (48). Thus, to understand whether prior infection shapes the functional potential of the mRNA vaccine-induced SARS-CoV-2 specific humoral immune response, we probed the ability of vaccine-induced antibodies to interact with the 4 low-affinity Fc-receptors in humans (Fc γ R2a, Fc γ R2b, Fc γ R3a, and Fc γ R3b) which largely direct innate immune effector functions (48, 49). Across all antigens, elevated FcR binding was noted in individuals who had previously been infected after the primary mRNA vaccine dose (Fig. 1C). After the second dose, naive vaccinees experienced a significant rise in FcR binding to all Fc γ Rs. Previously infected vaccinees did not experience any further maturation of the functional humoral immune response, although FcR binding remained higher for S2-specific Fc γ R2a and Fc γ R2b binding in previously infected individuals than in the naive individuals after the second dose. Viewed as a whole, there were clear qualitative differences in the architecture of the hybrid versus the naive immune response after the first and second doses of vaccine which were not fully explained by the net number of antigen exposures.

Previous infection expands the epitope-specific and functional SARS-CoV-2 response. Given the presence of striking univariate differences in both the overall breadth and the FcR binding profiles of vaccine-induced immune responses across the previously infected and naive vaccinees, we next aimed to define the features which differed the most across the SARS-CoV-2 specific immune profiles (Fig. 2). Specifically, we aimed to determine SARS-CoV-2-specific antibody profile differences after the first (V1) and second (V2) doses across the groups. A least absolute shrinkage and selection operator (LASSO) was first used to reduce the features to a minimal set of features which differed across the 2 groups, followed by a partial least-squares discriminant analysis (PLSDA) for visualization. Vaccine-induced antibody responses after the first vaccine dose (V1) could be clearly separated between previously infected and naive individuals (Fig. 2A; $P < 0.001$, permutation test; leave-one-out cross-validation [LOO-CV] accuracy = 1.0) based on as few as 4 of the




FIG 1 Isotype titers and Fc-receptor (FcR) binding for previously infected individuals after dose 1 are comparable to levels in naive individuals after dose 2. (A) Heatmap shows Z-scored SARS-CoV-2 specific antibody features for individuals post-prime and (Continued on next page)




FIG 2 Differences in antibody response following mRNA vaccination for previously infected individuals. (A) For the V1 data from all groups, a partial least-squares discriminant analysis (PLSDA) model was constructed to distinguish previously infected individuals from infection-naive individuals. In this model, individuals receiving the Pfizer-BioNTech and Moderna vaccines were combined within each class (prior infection versus infection-naive). Scatterplot shows latent variable scores, with each point representing a single individual. Ellipses represent 95% confidence intervals for each class. (B) Least absolute shrinkage and selection operator (LASSO) selection from the PLSDA model of V1 data from all groups. Bar plots show the contribution of each LASSO-selected antibody feature to the latent variables, sorted by VIP score (most important at the top). Bar color corresponds to the class with greater mean value for that feature. (C) For the V2 data from all groups, a PLSDA model similar to that in panel A was constructed to distinguish previously infected individuals from infection-naive individuals. Scatterplot shows latent variable scores. Ellipses represent 95% confidence intervals for each class. (D) LASSO selection from the PLSDA model of V2 data from all groups. Bar plots show the contribution of each LASSO-selected antibody feature to the latent variables, sorted by VIP score.

total 53 features collected per plasma sample (Fig. 2B). The 4 features were enriched among previously infected individuals and included S2-specific Fc γ R3a, RBD-specific Fc γ R3a, S2-specific IgG3, and NTD-specific IgG1 responses, indicating increased breadth of binding across the S2 and NTD as well as enhanced Fc γ R3a binding activity among previously infected individuals.

FIG 1 Legend (Continued)

post-boost. Each row is an individual sample, and each column is a measured feature. Features are clustered hierarchically, and individuals are also clustered within each group (infected/not infected and Pfizer-BioNTech/Moderna). Z-scores are calculated across all samples and truncated between -4 and 4. (B) Violin plots show individual subclasses specific for S1, receptor binding domain receptor binding domain (RBD), S2, and N-terminal domain (NTD) for infection-naive and previously infected individuals after 1st and 2nd vaccine doses. Significance was determined by a nonparametric Kruskal-Wallis test followed by Dunn's multiple-comparison test between pairs of groups. (C) Violin plots show low-affinity FcR binding by S1, RBD, S2, and NTD-specific antibodies for infection-naive and previously infected individuals after 1st and 2nd vaccine doses. Significance was determined by a nonparametric Kruskal-Wallis test followed by Dunn's multiple-comparison test between pairs of groups. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$.




FIG 3 Coordination between antibody isotypes, FcR binding, and antibody functions differs in previously infected individuals. (A) Spearman rank correlations ρ are shown between all pairs of features for previously infected individuals (above diagonal) and for naive individuals (below diagonal), combining samples from V1. Significant correlations after Benjamini-Hochberg correction with FDR < 0.05 are indicated with *. (B) Differences ($\rho_{\text{infection}} - \rho_{\text{no infection}}$) between correlations among previously infected and infection-naive individuals are shown for V1, where blue indicates more positive correlations among naive individuals. Correlation differences were computed using Fisher's Z-transformation, and significance was determined using bootstrap simulations. (C) Spearman rank correlations (ρ) are shown between all pairs of features for previously infected individuals (above diagonal) and naive individuals (below diagonal), combining samples from V2. Significant correlations after Benjamini-Hochberg correction with a false-discovery rate (FDR) of < 0.05 are indicated with an asterisk (*). (D) Differences ($\rho_{\text{infection}} - \rho_{\text{no infection}}$) between correlations among previously infected and among naive individuals are shown for V2, where blue indicates more positive correlations among naive individuals. Correlation differences were computed using Fisher's Z-transformation, and significance was determined using bootstrap simulations.

After the second dose, previously infected individuals still harbored a distinct SARS-CoV-2 specific antibody profile (Fig. 2C; $P < 0.001$, permutation test; LOO-CV accuracy = 0.981) compared to naive individuals. A total of 8 features were required to achieve separation between the 2 vaccine profiles, marked by 5 features that were elevated in infected individuals and 3 that were preferentially expanded in naive individuals (Fig. 2D). Specifically, S2-specific immunity was overall expanded among the previously infected group of vaccinees, including enhanced titers and FcR binding levels. Conversely, RBD- and Spike-specific IgG3 responses were selectively increased in naive vaccinees, consistent with the generation of new B cell responses in the setting of a more naive system, biased to the RBD and S1 domains.

Differences in coordination between antibody features for previously infected individuals. Given the significant differences in antibody responses across the previously infected and naive vaccinees, we finally aimed to determine whether previous infection drives a unique coordination in the humoral immune response induced by the SARS-CoV-2 vaccine (Fig. 3). As expected, we observed strong positive correlations between SARS-CoV-2-specific IgG titers and FcR binding among both infected and naive individuals (Fig. 3A). After the first vaccine dose (V1), enhanced correlation was observed between IgG3 responses and FcR binding among naive individuals which was not clearly

observed in previously infected individuals (Fig. 3A). IgM was more weakly correlated with FcR binding in previously infected individuals than in naive individuals. Moreover, after the first dose, a differential heatmap showed that IgG titers were more robustly correlated with antibody-dependent neutrophil phagocytic (ADNP) activity, whereas FcR-binding levels were more robustly associated with ADNP in naive individuals (Fig. 3B).

After V2, previously infected individuals continued to demonstrate poor correlation between IgG3 and FcR binding, and a weaker correlation between IgA1 and FcR binding, compared to infection-naive individuals (Fig. 3C). Conversely, naive individuals had poor correlation between subclass titers and FcR binding, and notably weaker correlation of S2-specific FcR engagement, compared with previously infected individuals. ADNP activity was positively correlated across IgG subclasses and FcRs in naive individuals and negatively correlated across FcR binding in previously infected individuals, suggesting a shift in previously infected individuals away from ADNP as a dominant effector function. Moreover, significant differences were noted in the correlations between FcR binding in ADNP across the groups, with IgG3-driven ADNP in previously infected individuals and a more diffuse role of FcR-binding antibodies in driving ADNP among naive vaccinees. Inverse differences were observed in ADCD-driving antibodies, driven by a diffuse set of FcR binding antibodies among previously infected vaccinees, but IgA and IgM in naive vaccinees with a largely negative correlation of ADCD activity across IgG subclasses and Fc γ Rs. Moreover, the differential heatmap highlighted the presence of an overall shift toward more coordination in IgG titers and FcR binding and function among previously infected individuals, with an overall pink shade in the differential heatmap (Fig. 3D), marked by enhanced coordination of IgG1 titers with Fc γ R3a binding, enhanced coordination of antibody features with antibody dependent cellular monocyte phagocytosis (ADCP), NTD-specific IgA levels, and antibody-dependent complement deposition in previously infected individuals. Conversely, FcR binding was more highly coordinated across FcRs, across antigen specificities, among the naive individuals. Together, these results further highlight qualitative differences in antibody responses following vaccination in previously infected individuals.

DISCUSSION

Due to the slow global rollout of vaccines, much of the world population will have experienced SARS-CoV-2 infection prior to immunization (50). Along these lines, emerging data suggest qualitatively superior vaccine-induced humoral and cellular immune responses among individuals who were previously infected with SARS-CoV-2 compared with those who received the vaccine in the absence of prior exposure to the virus (26–28, 31, 32). However, beyond neutralizing antibody and cellular immunity, mounting data point to a potential role for Fc-effector functions in the control and clearance of infection. Specifically, opsonophagocytic activity has been linked to survival of severe disease (51), enhanced FcR binding has been linked to asymptomatic infection (8, 10), Fc-effector function has been linked to convalescent plasma therapy (52), and Fc-effector function plays a critical role in monoclonal therapeutic activity (53, 54). However, whether hybrid immunity alters Fc-effector function, potentially resulting in enhanced protection (55), has remained largely unknown.

In our study, we found clear differences in SARS-CoV-2 specific serum antibodies following vaccination between previously infected and naive individuals, with antibody responses of greater magnitude and epitope specificity in individuals vaccinated after prior infection. Although antibody levels approximated each other after V2, several important differences persisted in FcR responses and shifts in coordination of the immune response. We noted that previously infected individuals had lower RBD-IgG3 levels, pointing to enhanced class-switching, and enhanced FcR binding, marking the generation of potentially functionally optimized antibodies particularly targeting the S2-domain of the highly conserved segment of the Spike protein.

Interestingly, enhanced FcR binding in hybrid immunity was particularly skewed toward enhanced binding to Fc γ R2a and Fc γ R3a, the two activating FcRs in humans (56).

Due to its broad expression across immune cell types, particularly on myeloid cells, Fc γ R2a is poised to drive rapid and robust opsonophagocytosis. Conversely, Fc γ R3a is expressed in a slightly more restricted manner, on cytotoxic NK cells and mature myeloid cells, implicated in driving rapid cytotoxic granule release and myeloid activity, respectively. Thus, the selective induction and preserved elevated Fc γ R2a and Fc γ R3a antibodies may enable individuals with hybrid immunity to clear viruses and kill infected cells more aggressively, providing an advantage even in the face of the emergence of VOCs which evade neutralization.

A specific expansion of S2-specific FcR binding capacity was notable following hybrid immunity. Conversely, vaccination alone drove a S1-dominant response, likely due to the stabilized nature of the Spike antigen in the mRNA vaccines (57, 58) which likely renders S2 slightly less visible to the immune response. However, during viral infection, copious copies of Spike are produced which are presented to the immune system as trimers, monomers, and S1 or S2 components. This heterogeneous presentation likely breaches the stabilized-vaccine immunodominance of S1, providing a unique opportunity for the hybrid immune response to generate immunity to the conserved S2 segment of Spike. Along these lines, the S2 domain is highly conserved across VOCs, with only 6 amino acid substitutions in S2 in Omicron (59) and high conservation across beta coronaviruses (60). Given our emerging appreciation for the disease-attenuating, rather than disease-blocking, functions of S2-specific antibodies (61) which are mediated largely via Fc-effector functions (60), these data argue that hybrid immune induction of potentially cross-reactive, functional antibodies to S2 may contribute to more robust protection against VOCs.

While this analysis did not capture differences in the quality of the hybrid immune response induced following infection with distinct VOCs, this study highlights an important role for hybrid immunity in driving expanded Fc-effector functions. Thus, beyond improved levels of neutralization (6) and T cell immunity, induced by hybrid immunity, this study highlights an additional aspect of expanded non-neutralizing antibody Fc-effector function (28, 29). Future studies evaluating the effects of hybrid immunity on FcR binding and Fc-effector functions in the setting of a heterologous combination of Spike exposures, as with an initial VOC infection preceding vaccination, will be critical to understanding the role of potential immune imprinting and the impact of homologous versus heterologous Spike challenge on Fc interactions and downstream effector functions which may play important ancillary roles in protection.

Given the small size of the cohort, we were unable to account for the different potential effects of Moderna mRNA-1273 and Pfizer-BNT162b2, nor did we evaluate other non-mRNA vaccine platforms. Despite these limitations, this study highlights valuable qualitative differences in the hybrid immune response not captured in previous studies. While comparable antibody titers after an equal number of total antigenic exposures (natural infection or vaccine) suggest natural infection as an interchangeable priming event with V1 in naive individuals, this study instead highlights qualitative advantages in the hybrid immune response which may offer potential improvements in vaccine development and merit longer term follow-up studies to understand the durability of these differences.

MATERIALS AND METHODS

Study population. Health services workers at the University of California, Los Angeles (UCLA) and first responders in the Los Angeles County Fire Department (LACoFD) were enrolled in a longitudinal cohort study assessing rates of SARS-CoV-2 infection in high-risk individuals (Table 1) (35). Eligible participants were over 18 years of age and free of symptoms associated with COVID-19 prior to enrollment. Participants were asked to provide monthly blood samples and up to biweekly, self-collected, mid-turbinate nasal swabs. Enrollment began in April 2020. In December 2020, two companies, Pfizer-BioNTech and Moderna, were granted emergency use authorizations (EUA) in the USA for their mRNA-based SARS-CoV-2 vaccines encoding the spike (S) protein. Both UCLA Health and LACoFD began offering vaccines in December 2020. Participants had blood drawn between 7 days after the first vaccine dose and just prior to the second dose (up to 20 days after the first dose of BNT162b2 and up to 27 days after the first dose of mRNA-1273). Blood was also collected 7 to 30 days, 31 to 60 days, and 61 to 90 days after completion of the two-dose series. All samples were collected between June 29, 2020 and March 11, 2021. Not all

TABLE 1 Baseline characteristics and demographic data of the study population

Characteristics	Vaccination type, n (%)				Immune status, n (%)				
	Total, n (%)	Moderna	Pfizer-BioNTech	AZ/Pfizer (excluded)	Not vaccinated (excluded)	Vaccinated, never infected	Infection prior to vaccination	Infected between doses (excluded)	Not vaccinated (excluded)
Total	68	27 (39.7)	39 (57.4)	1 (1.5)	1 (1.5)	49 (72.1)	14 (20.6)	4 (5.6)	1 (1.5)
Gender									
Female	35 (51.5)	3 (8.6)	31 (88.6)	—	1 (2.9)	27 (77.1)	4 (11.4)	3 (85.7)	1
Male	32 (47.1)	24 (75)	7 (21.9)	1 (3.1)	—	21 (65.6)	10 (31.3)	1 (3.1)	—
Prefer not to say	1 (1.5)	— ^a	1	—	—	1	—	—	—
Age (yrs)									
20–29	8 (11.8)	3	5	—	—	4	3	1	—
30–39	15 (22.1)	3	12	—	—	11	2	2	—
40–49	15 (22.1)	7	8	—	—	11	4	0	—
50–59	22 (32.4)	11	9	1	1	15	5	1	1
60–69	8 (11.8)	3	5	—	—	8	0	0	—
Ethnicity									
Hispanic/Latinx	11 (16.2)	8	3	—	—	8	2	1	—
Non-Hispanic	50 (73.5)	15	33	1	1	38	9	2	1
Prefer not to say	3 (4.4)	1	2	—	—	1	1	1	—
Race									
White	44 (64.7)	16	27	—	1	32	9	2	1
Black/African	3 (4.4)	2	1	—	—	1	1	1	—
Asian	10 (14.7)	1	8	1	—	9	1	—	—
American Indian/Alaskan native	1 (1.5)	1	—	—	—	1	—	—	—
Other	4 (5.6)	3	1	—	—	3	1	—	—
Prefer not to say	2 (2.9)	1	1	—	—	1	1	—	—
Immunity status									
Vaccinated, never infected	49 (72.1)	13	34	1	—	—	—	—	—
Infection prior to vaccination	14 (20.6)	11	3	—	—	—	—	—	—
Infected between doses (excluded)	4 (5.6)	1	3	—	—	—	—	—	—
Not vaccinated (excluded)	1 (1.5)	—	—	—	1	—	—	—	—

^adash indicates none.

participants provided blood samples at every time point. Only individuals receiving the Moderna or Pfizer-BioNTech vaccine and those who had been infected prior to the first dose or not at all were retained for analysis ($n = 63$). In particular, four individuals who had become infected between doses were excluded.

Antigens. The antigens used for Luminex-based assays are as follows: SARS-CoV-2 D614G WT S (provided by Erica Saphire, La Jolla Institute for Immunology), SARS-CoV-2 S1 (Sino Biological), SARS-CoV-2 S2 (Sino Biological) and SARS-CoV-2 RBD (kindly provided by Aaron Schmidt, Ragon Institute), and SARS-CoV-2 NTD (Sino Biological).

Biophysical antibody profiling. Serum samples were analyzed by customized Luminex assay to quantify the relative concentrations of antigen-specific antibody isotypes, subclasses, and Fc γ -receptor (Fc γ R) binding profiles, as previously described (36, 37). SARS-CoV-2 antigens coupled to Luminex beads with different fluorescences were used to profile SARS-CoV-2 antigen-specific humoral immune responses in a high-throughput, multiplexed assay. Antigens were coupled to magnetic Luminex beads (Luminex Corp.) by carbodiimide-NHS ester-coupling (Thermo Fisher). Antigen-coupled microspheres were washed and incubated with plasma samples at an appropriate sample dilution, based on performed dilution curves (1:500 for IgG1, 1:1,000 for all low affinity Fc γ -receptors, and 1:100 for all other readouts) for 2 h at 37°C in 384-well plates (Greiner Bio-One). Unbound antibodies were washed away, and antigen-bound antibodies were detected by using a PE-coupled detection antibody for each subclass and isotype (IgG1, IgG2, IgG3, IgG4, IgA1, and IgM; Southern Biotech), and Fc γ -receptors were fluorescently labeled with PE before addition to immune complexes (Fc γ R2a, Fc γ R2b, Fc γ R3a, Fc γ R3b; Duke Protein Production facility). Plates were incubated for 1 h, washed, and then flow cytometry was performed on an iQue (IntelliCyt) platform and analysis was performed using IntelliCyt ForeCyt (v8.1). Relative antigen-specific antibody titers are reported as PE median fluorescent intensity (MFI).

Antibody-dependent complement deposition. Antibody-dependent complement deposition was conducted as previously described (38). Briefly, SARS-CoV-2 antigens were coupled to magnetic Luminex beads (Luminex Corp.) by carbodiimide-NHS ester-coupling (Thermo Fisher). Coupled beads were incubated for 2 h at 37°C with serum samples (1:10 dilution) to form immune complexes and then washed to remove unbound immunoglobulins. Lyophilized guinea pig complement (Cedarlane) was diluted in gelatin veronal buffer with calcium and magnesium (GBV++; Boston BioProducts) and added to immune complexes to measure antibody-dependent deposition of C3. C3 was then detected with an anti-C3 fluorescein-conjugated goat IgG fraction detection antibody (MP Bio). Flow cytometry was performed using iQue (IntelliCyt) and an S-Lab robot (PAA). ADCD was reported as the median fluorescence of C3 deposition.

Antibody-dependent cellular and neutrophil phagocytosis. Antibody-dependent cellular phagocytosis and antibody-dependent neutrophil phagocytosis assays were conducted according to previously described protocols (39, 40). SARS-CoV-2 antigens were biotinylated using EDC (Thermo Fisher) and Sulfo-NHS-LCLC biotin (Thermo Fisher) and coupled to yellow-green (505/515) fluorescent Neutravidin-conjugated beads (Thermo Fisher). Immune complexes were formed by incubating antigen-coupled beads for 2 h at 37°C with 1:100-diluted serum samples, then washed to remove unbound immunoglobulins. For ADCP, the immune complexes were incubated for 16 to 18 h with THP-1 cells (1.25×10^5 THP-1 cells/mL); and for ADNP, for 1 h with RBC-lysed whole blood. After incubation, cells were fixed with 4% paraformaldehyde (PFA). For ADNP, RBC-lysed whole blood was washed, stained for CD66b+ (Biolegend) to identify neutrophils, and fixed in 4% PFA. An iQue (IntelliCyt) platform was used to perform flow cytometry to identify the percentage of cells which had phagocytosed beads and the number of beads that had been phagocytosed. Phagocytic function is reported as a phagocytosis score (phagocytosis score = % positive cells \times MFI of positive cells/10,000). Analysis was performed using IntelliCyt ForeCyt (v8.1).

Batch correction. Luminex experiments across samples were performed as described previously (41). Linear mixed-effects modeling was used to remove batch effects from the data while preserving the biological sources of variation that were of interest. In particular, for each feature measured, a linear mixed-effects model was fit to the data with terms accounting for fixed group effects (g_i), random batch effects (b_j), and random group-specific batch effects (gb_{ij}):

$$(\log\text{MFI})_{ijk} = \mu + g_i + b_j + (gb)_{ij} + \epsilon_{ijk}$$

with terms described in Table S1 in the supplemental material. Linear mixed-effect models were fit using the lme4 package (v1.1 to 27.1) in R version 4.1.0 (42). Batch-corrected values were then computed by subtracting the batch effects from each measurement:

$$(\log\text{MFI})_{ijk,\text{corrected}} = (\log\text{MFI})_{ijk} - b_j - (gb)_{ij}$$

Furthermore, all subsequent analysis on batch-corrected data was confirmed to be consistent with analysis performed on a single batch.

Univariate analysis. Univariate statistical analyses were performed using GraphPad Prism v9.1.2 for macOS. For each feature, comparisons were made between the four vaccinee groups—previously infected and naive individuals, after their first or second doses—using a nonparametric Kruskal-Wallis test followed by Dunn's multiple-comparison test between all pairs of groups.

Multivariate analysis. Multivariate analysis was performed in R (v4.1.0). Measurements for each feature were first \log_{10} -transformed, then centered and scaled. For classification models, LASSO feature selection was performed using the systemsseRology R package (v1.1) (<https://github.com/LoosC/systemsseRology>) (43). LASSO selection was repeated 50 times, and features that were selected in at

least 20% of trials were kept. To discriminate antibody features from previously infected and naive individuals, partial least-squares discriminant analysis was performed using the LASSO-selected features. The importance of individual features was assessed using variable importance in projection (VIP) scores (44). Model performance and robustness were assessed using cross-validation, which was compared to control models trained with random features or permuted labels. Separate models were built for each time point to distinguish samples from previously infected and naive individuals, and recipients of Moderna and Pfizer-BioNTech vaccines were combined in the analysis. A LASSO-PLSDA model was also built to distinguish antibody features at different time points using all the samples.

For correlation analyses, Spearman correlations were computed between all pairs of antibody features, and multiple comparisons were handled using a Benjamini-Hochberg correction with false-discovery rate (FDR) < 0.05 (45). To compare correlations between samples from previously infected and naive individuals, a Fisher's Z-transformation of the correlation coefficients was computed (46). Testing for significance was performed using bootstrap simulations with the bootcorci R package (v0.0.0.9000) (<https://github.com/GRousselet/bootcorci>) (47).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

TABLE S1, PDF file, 0.1 MB.

ACKNOWLEDGMENTS

We thank Mark and Lisa Schwartz, Terry and Susan Ragon, and the SAMANA Kay MGH Research Scholars award for their support. Funding was received from the Massachusetts Consortium on Pathogen Readiness (MassCPR), the NIH (3R37AI080289-11S1, R01AI146785, U19AI42790-01, U19AI135995-02, U19AI42790-01, 1U01CA260476-01, CIVIC75N93019C00052) and the NIH training grant 5T32 AI007387-32.

G.A. is a founder/equity holder in Seroymx Systems and Leyden Labs. G.A. has served as a scientific advisor for Sanofi Vaccines. G.A. has collaborative agreements with GSK, Merck, Sanofi, Medicago, BioNtech, Moderna, BMS, Novavax, SK Biosciences, Gilead, and Sanaria. All other authors have no disclosures.

REFERENCES

- Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, Groome MJ, Huppert A, O'Brien KL, Smith PG, Wilder-Smith A, Zeger S, Deloria Knoll M, Patel MK. 2022. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *Lancet* 399:924–944. [https://doi.org/10.1016/S0140-6736\(22\)00152-0](https://doi.org/10.1016/S0140-6736(22)00152-0).
- Walensky RP, Walke HT, Fauci AS. 2021. SARS-CoV-2 variants of concern in the United States: challenges and opportunities. *JAMA* 325:1037–1038. <https://doi.org/10.1001/jama.2021.2294>.
- Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, Giattino C, Rod s-Guirao L. 2021. A global database of COVID-19 vaccinations. *Nat Hum Behav* 5:947–953. <https://doi.org/10.1038/s41562-021-01122-8>.
- McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, Liu J, Peter L, Atyeo C, Zhu A, Bondzie EA, Dagotto G, Gebre MS, Jacob-Dolan C, Li Z, Nampanya F, Patel S, Pessaint L, Van Ry A, Blade K, Yalley-Ogunro J, Cabus M, Brown R, Cook A, Teow E, Andersen H, Lewis MG, Lauffenburger DA, Alter G, Barouch DH. 2021. Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature* 590:630–634. <https://doi.org/10.1038/s41586-020-03041-6>.
- Molodtsov IA, Kegeles E, Mitin AN, Mityaeva O, Musatova OE, Panova AE, Pashenkov MV, Peshkova IO, Alsalloum A, Asaad W, Budikhina AS, Deryabin AS, Dolzhikova IV, Filimonova IN, Gracheva AN, Ivanova OI, Kizilova A, Komogorova VV, Komova A, Kompantseva NI, Kucheryavikh E, Lagutkin DA, Lomakin YA, Maleeva AV, Maryukhnich EV, Mohammad A, Murugin VV, Murugina NE, Navoikova A, Nikonova MF, Ovchinnikova LA, Panarina Y, Pinegina NV, Potashnikova DM, Romanova EV, Saidova AA, Sakr N, SamoiloVA AG, Serdyuk Y, Shakirova NT, Sharova NI, Sheetikov SA, Shemetova AF, Shevkova LV, Shpektor AV, Trufanova A, Tvorogova AV, Ukrainskaya VM, Vinokurov AS, Vorobyeva DA, et al. 2022. SARS-CoV-2-specific T cells and antibodies in COVID-19 protection: a prospective study. *Clin Infect Dis* ciac278. Online ahead of print. <https://doi.org/10.1093/cid/ciac278>.
- R ltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, Hunter M, Wang H, Sahoo MK, Huang C, Yamamoto F, Manohar M, Manalac J, Otrelo-Cardoso AR, Pham TD, Rustagi A, Rogers AJ, Shah NH, Blish CA, Cochran JR, Jardetzky TS, Zehnder JL, Wang TT, Narasimhan B, Gombar S, Tibshirani R, Nadeau KC, Kim PS, Pinsky BA, Boyd SD. 2020. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. *Sci Immunol* 5:eabe0240. <https://doi.org/10.1126/sciimmunol.abe0240>.
- Adeniji OS, Giron LB, Purwar M, Zilberstein NF, Kulkarni AJ, Shaikh MW, Balk RA, Moy JN, Forsyth CB, Liu Q, Dweep H, Kossenkov A, Weiner DB, Keshavarzian A, Landay A, Abdel-Mohsen M. 2021. COVID-19 severity is associated with differential antibody Fc-mediated innate immune functions. *mBio* 12. <https://doi.org/10.1128/mBio.00281-21>.
- Zohar T, Loos C, Fischinger S, Atyeo C, Wang C, Slein MD, Burke J, Yu J, Feldman J, Hauser BM, Caradonna T, Schmidt AG, Cai Y, Streeck H, Ryan ET, Barouch DH, Charles RC, Lauffenburger DA, Alter G. 2020. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. *Cell* 183:1508–1519.e12. <https://doi.org/10.1016/j.cell.2020.10.052>.
- Lee WS, Selva KJ, Davis SK, Wines BD, Reynaldi A, Esterbauer R, Kelly HG, Haycroft ER, Tan H-X, Juno JA, Wheatley AK, Hogarth PM, Cromer D, Davenport MP, Chung AW, Kent SJ. 2021. Decay of Fc-dependent antibody functions after mild to moderate COVID-19. *Cell Rep Med* 2:100296. <https://doi.org/10.1016/J.XCRM.2021.100296>.
- Kaplonek P, Wang C, Bartsch Y, Fischinger S, Gorman MJ, Bowman K, Kang J, Dayal D, Martin P, Nowak RP, Villani AC, Hsieh CL, Charland NC, Gonye ALK, Gushterova I, Khanna HK, LaSalle TJ, Lavin-Parsons KM, Lilley BM, Lodenstein CL, Manakongtreecheep K, Margolin JD, McKaig BN, Rojas-Lopez M, Russo BC, Sharma N, Tantivit J, Thomas MF, Sade-Feldman M, Feldman J, Julg B, Nilles EJ, Musk ER, Menon AS, Fischer ES, McLellan JS, Schmidt A, Goldberg MB, Filbin MR, Hacohen N, Lauffenburger DA, Alter G. 2021. Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. *Sci Immunol* 6:eabj2901. <https://doi.org/10.1126/sciimmunol.abj2901>.
- Bournazos S, Corti D, Virgin HW, Ravetch JV. 2020. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. *Nature* 588:485–490. <https://doi.org/10.1038/s41586-020-2838-z>.
- Dillillo DJ, Tan GS, Palese P, Ravetch JV. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection

- against influenza virus *in vivo*. *Nat Med* 20:143–151. <https://doi.org/10.1038/nm.3443>.
13. Bournazos S, DiLillo DJ, Goff AJ, Glass PJ, Ravetch JV. 2019. Differential requirements for Fc γ R engagement by protective antibodies against Ebola virus. *Proc Natl Acad Sci U S A* 116:20054–20062. <https://doi.org/10.1073/pnas.1911842116>.
 14. Boero E, Cruz AR, Pansegrau W, Giovanni C, Rooijackers SHM, van Kessel KPM, van Strijp JAG, Bagnoli F, Manetti AGO. 2022. Natural human immunity against staphylococcal protein A relies on effector functions triggered by IgG3. *Front Immunol* 13:834711. <https://doi.org/10.3389/fimmu.2022.834711>.
 15. Kawahara JY, Irvine EB, Alter G. 2019. A case for antibodies as mechanistic correlates of immunity in tuberculosis. *Front Immunol* 10:996. <https://doi.org/10.3389/fimmu.2019.00996>.
 16. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, Gallagher E, Thelwall S, Groves N, Dabrera G, Myers R, Campbell CNJ, Amirhalingam G, Edmunds M, Zambon M, Brown K, Hopkins S, Chand M, Ladhani SN, Ramsay M, Lopez Bernal J. 2022. Duration of protection against mild and severe disease by COVID-19 vaccines. *N Engl J Med* 386:340–350. <https://doi.org/10.1056/NEJMoa2115481>.
 17. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, Al Khatib HA, Coyle P, Ayoub HH, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Al Romaihi HE, Butt AA, Al-Thani MH, Al Khal A, Bertollini R, Abu-Raddad LJ. 2021. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. *N Engl J Med* 385:e83. <https://doi.org/10.1056/NEJMoa2114114>.
 18. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, Doolman R, Asraf K, Mendelson E, Ziv A, Rubin C, Freedman L, Kreiss Y, Regev-Yochay G. 2021. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. *N Engl J Med* 385:e84. <https://doi.org/10.1056/NEJMoa2114583>.
 19. Mbaeyi S, Oliver SE, Collins JP, Godfrey M, Goswami ND, Hadler SC, Jones J, Moline H, Moulia D, Reddy S, Schmit K, Wallace M, Chamberland M, Campos-Outcalt D, Morgan RL, Bell BP, Brooks O, Kotton C, Talbot HK, Lee G, Daley MF, Dooling K. 2021. The Advisory Committee on Immunization Practices' interim recommendations for additional primary and booster doses of COVID-19 vaccines: United States, 2021. *MMWR Morb Mortal Wkly Rep* 70:1545–1552. <https://doi.org/10.15585/mmwr.mm7044e2>.
 20. CDC. 2019. COVID-19 Vaccine Boosters. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html?_cid=11706:covid%20vaccine%20booster%20dose.sem.ga.p:RG:GM:gen:PTN:FY22. Retrieved May 31, 2022. CDC, Atlanta, GA.
 21. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. 2021. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *Lancet* 397:1204–1212. [https://doi.org/10.1016/S0140-6736\(21\)00575-4](https://doi.org/10.1016/S0140-6736(21)00575-4).
 22. Sheehan MM, Reddy AJ, Rothberg MB. 2021. Reinfection rates among patients who previously tested positive for coronavirus disease 2019: a retrospective cohort study. *Clin Infect Dis* 73:1882–1886. <https://doi.org/10.1093/cid/ciab234>.
 23. Vitale J, Mumoli N, Clerici P, De Paschale M, Evangelista I, Cei M, Mazzone A. 2021. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy. *JAMA Intern Med* 181:1407–1408. <https://doi.org/10.1001/jamainternmed.2021.2959>.
 24. León TM, Dorabawila V, Nelson L, Lutterloh E, Bauer UE, Backenson B, Bassett MT, Henry H, Bregman B, Midgley CM, Myers JF, Plumb ID, Reese HE, Zhao R, Briggs-Hagen M, Hoefler D, Watt JP, Silk BJ, Jain S, Rosenberg ES. 2022. COVID-19 cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis: California and New York, May–November 2021. *MMWR Morb Mortal Wkly Rep* 71:125–131. <https://doi.org/10.15585/mmwr.mm7104e1>.
 25. Siracusano G, Ruggiero A, Bisoffi Z, Piubelli C, Carbonare LD, Valenti MT, Mayora-Neto M, Temperton N, Lopalco L, Zipeto D. 2022. Different decay of antibody response and VOC sensitivity in naive and previously infected subjects at 15 weeks following vaccination with BNT162b2. *J Transl Med* 20:22. <https://doi.org/10.1186/s12967-021-03208-3>.
 26. Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, Sajadi MM. 2021. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. *JAMA* 325:1467–1469. <https://doi.org/10.1001/jama.2021.3341>.
 27. Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, Lei T, Thapa M, Chen RE, Case JB, Amanat F, Rauseo AM, Haile A, Xie X, Klebert MK, Suessen T, Middleton WD, Shi P-Y, Krammer F, Teefey SA, Diamond MS, Presti RM, Ellebedy AH. 2021. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. *Nature* 596:109–113. <https://doi.org/10.1038/s41586-021-03738-2>.
 28. Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, Gouma S, Hicks P, Meng W, Rosenfeld AM, Dysinger S, Lundgreen KA, Kuri-Cervantes L, Adamski S, Hicks A, Korte S, Oldridge DA, Baxter AE, Giles JR, Weirick ME, McAllister CM, Dougherty J, Long S, D'Andrea K, Hamilton JT, Betts MR, Luning Prak ET, Bates P, Hensley SE, Greenplate AR, Wherry EJ. 2021. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. *Sci Immunol* 6:eabi6950. <https://doi.org/10.1126/sciimmunol.abi6950>.
 29. Wang Z, Muecksch F, Schaefer-Babajew D, Fink S, Viant C, Gaebler C, Hoffmann Hans-H, Barnes CO, Cipolla M, Ramos V, Oliveira TY, Cho A, Schmidt F, Da Silva J, Bednarski E, Aguado L, Yee J, Daga M, Turroja M, Millard KG, Jankovic M, Gazumyan A, Zhao Z, Rice CM, Bieniasz PD, Caskey M, Hatzioannou T, Nussenzweig MC. 2021. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature* 595:426–431. <https://doi.org/10.1038/s41586-021-03696-9>.
 30. Bates TA, McBride SK, Leier HC, Guzman G, Lyski ZL, Schoen D, Winders B, Lee JY, Lee DX, Messer WB, Curlin ME, Tafesse FG. 2022. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. *Sci Immunol* 7:eabn8014. <https://doi.org/10.1126/sciimmunol.abn8014>.
 31. Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Probst JC, Frias EC, Stewar JL, Van Eyk JE, Braun JG, Cheng S, Sobhani K. 2021. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. *Nat Med* 27:981–984. <https://doi.org/10.1038/s41591-021-01325-6>.
 32. Rodda LB, Morawski PA, Pruner KB, Fahning ML, Howard CA, Franko N, Logue J, Eggenberger J, Stokes C, Golez I, Hale M, Gale M, Chu HY, Campbell DJ, Pepper M. 2022. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. *Cell* 185:1588.e14–1601.e14. <https://doi.org/10.1016/j.cell.2022.03.018>.
 33. Taus E, Hofmann C, Ibarondo FJ, Hausner MA, Fulcher JA, Krogstad P, Ferbas KG, Tobin NH, Rimoin AW, Aldrovandi GM, Yang OO. 2022. Dominant CD8⁺ T cell nucleocapsid targeting in SARS-CoV-2 infection and broad Spike targeting from vaccination. *Front Immunol* 13:835830. <https://doi.org/10.3389/fimmu.2022.835830>.
 34. Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, Bermúdez-González MC, Bielak DA, Carreño JM, Chernet RL, Eaker LQ, Ferreri ED, Floda DL, Gleason CR, Hamburger JZ, Jiang K, Kleiner G, Jurczynski D, Matthews JC, Mendez WA, Nabeel I, Mulder LCF, Raskin AJ, Russo KT, Salimbangon A-BT, Saksena M, Shin AS, Singh G, Sominsky LA, Stadlbauer D, Wajnberg A, Simon V. 2021. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. *N Engl J Med* 384:1372–1374. <https://doi.org/10.1056/NEJMc2101667>.
 35. Gadoth A, Halbrook M, Martin-Blais R, Gray A, Tobin NH, Ferbas KG, Aldrovandi GM, Rimoin AW. 2021. Cross-sectional assessment of COVID-19 vaccine acceptance among health care workers in Los Angeles. *Ann Intern Med* 174:882–885. <https://doi.org/10.7326/M20-7580>.
 36. Brown EP, Licht AF, Dugast A-S, Choi I, Bailey-Kellogg C, Alter G, Ackerman ME. 2012. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. *J Immunol Methods* 386:117–123. <https://doi.org/10.1016/j.jim.2012.09.007>.
 37. Brown EP, Dowell KG, Boesch AW, Normandin E, Mahan AE, Chu T, Barouch DH, Bailey-Kellogg C, Alter G, Ackerman ME. 2017. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. *J Immunol Methods* 443:33–44. <https://doi.org/10.1016/j.jim.2017.01.010>.
 38. Fischinger S, Fallon JK, Michell AR, Broge T, Suscovich TJ, Streeck H, Alter G. 2019. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. *J Immunol Methods* 473:112630. <https://doi.org/10.1016/j.jim.2019.07.002>.
 39. Butler AL, Fallon JK, Alter G. 2019. A sample-sparing multiplexed ADPC assay. *Front Immunol* 10:1851. <https://doi.org/10.3389/fimmu.2019.01851>.
 40. Karsten CB, Mehta N, Shin SA, Diefenbach TJ, Slein MD, Karpinski W, Irvine EB, Broge T, Suscovich TJ, Alter G. 2019. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis. *J Immunol Methods* 471:46–56. <https://doi.org/10.1016/j.jim.2019.05.006>.
 41. Clarke DC, Morris MK, Lauffenburger DA. 2013. Normalization and statistical analysis of multiplexed bead-based immunoassay data using mixed-effects modeling. *Mol Cell Proteomics* 12:245–262. <https://doi.org/10.1074/mcp.M112.018655>.

42. Bates D, Mächler M, Bolker BM, Walker SC. 2015. Fitting linear mixed-effects models using lme4. *J Stat Softw* 67. <https://doi.org/10.18637/jss.v067.i01>.
43. Friedman J, Hastie T, Tibshirani R. 2010. Regularization paths for generalized linear models via coordinate descent. *J Stat Softw* 33:1–22.
44. Mehmood T, Liland KH, Snipen L, Sæbø S. 2012. A review of variable selection methods in Partial Least Squares Regression. *Chemometrics Intelligent Lab Sys* 118:62–69. <https://doi.org/10.1016/j.chemolab.2012.07.010>.
45. Benjamini Y, Yekutieli D. 2001. The control of the false discovery rate in multiple testing under dependency. *Ann Statist* 29:1165–1188. <https://doi.org/10.1214/aos/1013699998>.
46. Myers L, Sirois MJ. 2006. Spearman correlation coefficients, differences between. In Kotz S, Read CB, Balakrishnan N, Vidakovic B (ed), *Encyclopedia of statistical sciences*, 12th ed. <https://doi.org/10.1002/0471667196.ess5050.pub2>. John Wiley & Sons, Inc., Hoboken, NJ.
47. Rousselet G, Pernet DC, Wilcox RR. A practical introduction to the bootstrap: a versatile method to make inferences by using data-driven simulations. <https://doi.org/10.31234/OSF.IO/H8FT7>.
48. Bournazos S, Woof JM, Hart SP, Dransfield I. 2009. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. *Clin Exp Immunol* 157:244–254. <https://doi.org/10.1111/j.1365-2249.2009.03980.x>.
49. Boudreau CM, Alter G. 2019. Extra-neutralizing FcR-mediated antibody functions for a universal influenza vaccine. *Front Immunol* 10:440. <https://doi.org/10.3389/FIMMU.2019.00440>.
50. World Health Organization. WHO COVID-19 dashboard. Available online at <https://covid19.who.int/>. Retrieved 20 April, 2022. WHO, Geneva, Switzerland.
51. Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, McCulloch DJ, Newman KL, Wolf C, Yu J, Shuey K, Feldman J, Hauser BM, Caradonna T, Schmidt AG, Suscovich TJ, Linde C, Cai Y, Barouch D, Ryan ET, Charles RC, Lauffenburger D, Chu H, Alter G. 2020. Distinct early serological signatures track with SARS-CoV-2 survival. *Immunity* 53:524.e4–532.e4. <https://doi.org/10.1016/j.immuni.2020.07.020>.
52. Herman JD, Wang C, Loos C, Yoon H, Rivera J, Eugenia Dieterle M, Haslwanter D, Jangra RK, Bortz RH, Bar KJ, Julg B, Chandran K, Lauffenburger D, Pirofski L-a, Alter G. 2021. Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. *Nat Commun* 12:6853. <https://doi.org/10.1038/s41467-021-27201-y>.
53. Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Chong Z, Zost SJ, Jang H, Huang Y, Allen JD, Case JB, Sutton RE, Carnahan RH, Darling TL, Boon ACM, Mack M, Head RD, Ross TM, Crowe JE, Diamond MS. 2021. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. *Cell* 184:1804.e16–1820.e16. <https://doi.org/10.1016/j.cell.2021.02.026>.
54. Schäfer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, Schmidt F, Maison RM, Gazumyan A, Martinez DR, Baric RS, Robbiani DF, Hatzioannou T, Ravetch JV, Bieniasz PD, Bowen RA, Nussenzweig MC, Sheahan TP. 2021. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection *in vivo*. *J Exp Med* 218:e20201993. <https://doi.org/10.1084/jem.20201993>.
55. Nordström P, Ballin M, Nordström A. 2022. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. *Lancet Infect Dis* 22:781–790. [https://doi.org/10.1016/S1473-3099\(22\)00143-8](https://doi.org/10.1016/S1473-3099(22)00143-8).
56. Nimmerjahn F, Ravetch JV. 2008. Fcγ receptors as regulators of immune responses. *Nat Rev Immunol* 8:34–47. <https://doi.org/10.1038/nri2206>.
57. Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong W-P, Andres EL, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS. 2017. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. *Proc Natl Acad Sci U S A* 114:E7348–E7357. <https://doi.org/10.1073/pnas.1707304114>.
58. Dai L, Gao GF. 2021. Viral targets for vaccines against COVID-19. *Nat Rev Immunol* 21:73–82. <https://doi.org/10.1038/s41577-020-00480-0>.
59. Ou J, Lan W, Wu X, Zhao T, Duan B, Yang P, Ren Y, Quan L, Zhao W, Seto D, Chodosh J, Luo Z, Wu J, Zhang Q. 2022. Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events. *Signal Transduct Target Ther* 7:138. <https://doi.org/10.1038/s41392-022-00992-2>.
60. Zhou P, Yuan M, Song G, Beutler N, Shaabani N, Huang D, He W-t, Zhu X, Callaghan S, Yong P, Anzanello F, Peng L, Ricketts J, Parren M, Garcia E, Rawlings SA, Smith DM, Nemazee D, Teijaro JR, Rogers TF, Wilson IA, Burton DR, Andrabi R. 2022. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. *Sci Transl Med* 14:eabi9215. <https://doi.org/10.1126/scitranslmed.abi9215>.
61. Hu J, Chen X, Lu X, Wu L, Yin L, Zhu L, Liang H, Xu F, Zhou Q. 2022. A spike protein S2 antibody efficiently neutralizes the Omicron variant. *Cell Mol Immunol* 19:644–646. <https://doi.org/10.1038/s41423-022-00847-4>.